Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approach
Introduction
Due to ageing of the population and the rising incidence rates of most cancers with age, the mean age of patients diagnosed with cancer is increasing in western countries. This implies that they increasingly suffer from one or more other serious (chronic) diseases. Besides affecting the life expectancy, co-morbid conditions may complicate the treatment of cancer patients, especially when they are frail [1], [2], [3]. Since elderly patients are often excluded from clinical trials, little is known about treatment outcome, such as complications, quality of life and survival. Although the number of trials that include elderly is increasing, generally only relatively healthy elderly are included. This means that trial results may not be valid for many older cancer patients.
This study focuses on the prognostic role of increasing age and co-morbidity in cancer patients diagnosed in the registration area of the population-based Eindhoven Cancer Registry.
Section snippets
Methods
The Eindhoven Cancer Registry records data on all patients newly diagnosed with cancer in the southern part of the Netherlands, an area with 2.3 million inhabitants and only community hospitals [4]. Since 1993, serious co-morbidity with prognostic impact has been recorded for all patients. The Charlson co-morbidity index is most widely used for recording co-morbidity and was validated in various studies [5]. We used a slightly modified version of this index for recording co-morbidity (Table 1).
Prevalence of co-morbidity
The prevalence of co-morbidity usually increased with age (Table 2), but remained stable or decreased above age 80 for registered patients with pancreatic or lung cancer. About 60% of all new cancer patients older than 65 suffered from at least one other serious disease. The most frequent concomitant diseases were previous cancers, heart disease, hypertension, COPD and diabetes mellitus, with prevalence rates up to 20, 23, 26, 17 and 16%, respectively. The prevalence of cardiovascular diseases
Validity of data
Between 2001 and 2003 the completeness and accuracy of our data on co-morbidity in the Eindhoven Cancer registry were validated in a random sample of 2607 patients with colorectal, lung, breast and prostate cancer and non-Hodgkin's lymphoma aged 40 years and older and diagnosed between 1995 and 1999. Co-morbidity scored by the registry team was compared with that scored by a team of a retired surgeon and an epidemiologist. Some underregistration occurred, especially of cardiovascular conditions
Dr. Maryska L.G. Janssen-Heijnen is working as a senior epidemiologist at the Eindhoven Cancer Registry, The Netherlands. She focuses at prognostic factors for cancer patients, with a special interest in elderly patients with co-morbidity. Since 2000, she is co-ordinating a large population-based project in which the prevalence of co-morbidity in cancer patients is studied, as well as the influence of increasing age and co-morbidity on choice of treatment, complications of treatment and
References (40)
- et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data
J Clin Epidemiol
(1999) - et al.
A computer program package for relative survival analysis
Comput Programs Biomed
(1985) - et al.
Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study
Lung Cancer
(1998) - et al.
The epidemiology of endometrial cancer
Gynecol Oncol
(1991) - et al.
Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number
Eur J Cancer
(1998) - et al.
Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry
Eur J Cancer
(2005) - et al.
Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands
Ann Oncol
(1996) - et al.
Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study
Eur J Cancer
(2005) - et al.
Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer
Int J Radiat Oncol Biol Phys
(2002)
Comorbidity and karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies
Int J Radiat Oncol Biol Phys
Impact of comorbidity on survival after surgical resection in patients with stage I non-small cell lung cancer
J Thorac Cardiovasc Surg
The importance of classifying initial co-morbidity in evaluatin the outcome of diabetes mellitus
J Chronic Dis
Rating chronic medical illness burden in geropsychiatric practice and research: application of the cumulative illness rating scale
Psychiatry Res
Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base
J Clin Oncol
Comorbidity and functional status are independent in older cancer patients
J Clin Oncol
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study
J Clin Oncol
Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study
Eur J Gastroenterol Hepatol
Coffee and alcohol as determinants of risk of pancreas cancer: a case-control study from Toronto
Int J Cancer
Cited by (318)
Gastric adenocarcinoma location and postoperative complication rates in Asian patients: A 2014–2019 NSQIP analysis
2024, American Journal of SurgeryGI factors, potential to predict prostate motion during radiotherapy; a scoping review
2023, Clinical and Translational Radiation OncologyPopulation-based cancer survival in the Golestan province in the northeastern part of Iran 2007–2012
2022, Cancer EpidemiologyAssociations between the Geriatric-8 and 4-meter gait speed test and subsequent delivery of adjuvant chemotherapy in older patients with colon cancer
2021, Journal of Geriatric OncologyCitation Excerpt :To what extent guideline treatments are appropriate for older patients is largely unknown. This often leads to undertreatment and/or overtreatment of older patients with CRC with poorer survival or functional status as a result [5,6]. In addition, several previous studies have shown that surgical treatment for CRC in older patients was associated with increased postoperative morbidity and mortality [7,8].
Dr. Maryska L.G. Janssen-Heijnen is working as a senior epidemiologist at the Eindhoven Cancer Registry, The Netherlands. She focuses at prognostic factors for cancer patients, with a special interest in elderly patients with co-morbidity. Since 2000, she is co-ordinating a large population-based project in which the prevalence of co-morbidity in cancer patients is studied, as well as the influence of increasing age and co-morbidity on choice of treatment, complications of treatment and prognosis.